Key result
Standard LV failure therapies lack solid evidence of benefit in systemic right ventricular failure.
Why the study?
The evidence base for implementing left ventricular failure treatment regimens in patients with a systemic right ventricle is poor due to underpowered studies, short follow-up, or retrospective design.
Clinical use of ACE inhibitors and β-blockers in systemic right ventricle should remain cautious; leaves open the need for powered randomized trials.
To the editor: In the recent paper presenting the latest insights into the therapeutic options for patients with systemic right ventricles, Winter et al 1 argued that “the pragmatic use of angiotensin converting enzyme inhibitors and β blockers in these patients seems appropriate”. However, they also concluded that “the evidence base for the implementation of left ventricular failure treatment regimens in patients with a systemic right ventricle is poor” and that “most studies were underpowered, had short follow-up periods, or had a retrospective study set-up”. There is, however, another important reason for the failure to demonstrate the efficacy of angiotensin converting enzyme inhibitors, …
No takes yet. Share an insight, caveat, or question.
Szymański et al. (2009) conducted a letter in Systemic right ventricular failure. Angiotensin converting enzyme inhibitors and β blockers was evaluated. The evidence base for using left ventricular failure treatments like ACE inhibitors and beta-blockers in patients with systemic right ventricular failure remains poor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: